Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Cutting-edge fluorescent cholesterol probes now enable scientists to visualize cholesterol movement and distribution in live cells with unprecedented detail. By combining computer simulations with ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...

A Molecule Is Shown to Produce Cognitive Improvement in Rodents With Early Alzheimer's Disease Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling ...